RAS Peptide Profile in Healthy Volunteers
Conditions
Keywords
RAS-Peptide Profile, Renin-Angiotensin-System, Angiotensin-Converting-Enzyme-Inhibitor, Angiotensin-Receptor-Antagonist, Renin-inhibitor
Brief summary
The primary objective is the characterization of the RAS peptide profiles after single and repeated oral administration of a renin inhibitor, an ACE inhibitor and an angiotensin receptor blocker in healthy volunteers. Secondary objectives are the correlation of RAS peptide profiles with pharmacokinetic profiles of the different RAS inhibitors and with pharmacodynamic parameters such as blood pressure and heart rate. Output of the classic RAS system will be assessed using aldosterone concentrations. Fluid and sodium intake will be monitored using sodium concentration and total volume in 24h urine.
Detailed description
The results of a pilot study have shown that single doses of different RAS inhibitors produce characteristic changes of the RAS peptide profiles. In a first step this finding needs to be verified in a larger number of healthy subjects. Since it is unknown, whether the changes that were observed within hours after a single inhibitor dose are stable over time, the profiles also need to be investigated under steady-state conditions of the different inhibitors. Comparison of RAS peptide profiles after single dose and under steady-state conditions will also allow to detect whether the peptide profiles are altered by compensatory mechanisms.
Interventions
DRUGACEI-ARB-RI
DRUGARB-RI-ACEI
DRUGRI-ACEI-ARB
Sponsors
University Hospital, Basel, Switzerland
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Male aged between 18 and 45 years (inclusive) at screening. * Body mass index (BMI) between 18 and 28 kg/m2 (inclusive) and body weight at least 50 kg at screening. * Systolic blood pressure (SBP) 100-140 mmHg, diastolic blood pressure (DBP) 60-90 mmHg and heart rate (HR) 45-90 bpm (inclusive), measured on the leading arm\*, after 5 min in the supine position at screening. * Signed informed consent prior to any study-mandated procedure. * No clinically significant findings on the physical examination at screening. * 12-lead electrocardiogram (ECG) without clinically relevant abnormalities at screening. * Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent at screening. * Ability to communicate well with the investigator and to understand and comply with the requirements of the study. * leading arm right = writing with right hand
Exclusion criteria
* Smoking \> 5 cigarettes per day * History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. * Loss of ≥ 250 ml of blood within 3 months prior to screening. * Treatment with an investigational drug within 30 days prior to screening. * Previous treatment with any prescribed or over the counter medications (including herbal medicines such as St John's Wort) within 2 weeks prior to the intended start of study. * Legal incapacity or limited legal capacity at screening. * Positive results from urine drug screen at screening. * History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity. * Known hypersensitivity to any excipients of the drug formulations. * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RAS-peptide profile | 0-192h |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure and heart rate | 0-192 h |
| Aldosterone concentrations | 0-192 h |
Countries
Switzerland
Outcome results
None listed